NOVEL ANTIBODY AND ANTIBODY FRAGMENT INTRODUCED NEW MODIFICATION SITES
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.
-
Citations
34 Claims
-
1-20. -20. (canceled)
-
21. A method for producing an IgG monoclonal antibody or antigen-binding fragment thereof,
comprising culturing a transformant in a medium and recovering the monoclonal IgG antibody or the antigen-binding fragment thereof from the culture, wherein the monoclonal IgG antibody or the antigen-binding fragment thereof comprises a human constant region in which one or more amino acids are substituted with a cysteine residue, wherein said one or more amino acids that are substituted are selected from the group consisting of (1) to (5): -
(1) the amino acid at position 124 of human IgG light chain region in Kabat numbering, (2) the amino acid at position 198 of human IgG light chain region in Kabat numbering, (3) the amino acid at position 201 of human IgG light chain region in Kabat numbering, (4) the amino acid at position 147 of human IgG heavy chain region in EU numbering, and (5) the amino acid at position 183 of human IgG heavy chain region in EU numbering, and wherein the transformant comprises a recombinant vector comprising a DNA encoding the IgG monoclonal antibody or the antigen-binding fragment thereof. - View Dependent Claims (23, 24, 25, 30, 31, 32, 33, 34)
-
-
22. A method for producing an IgG monoclonal antibody or antigen-binding fragment thereof,
comprising culturing a transformant in a medium and recovering the monoclonal IgG antibody or the antigen-binding fragment thereof from the culture, wherein the monoclonal IgG antibody or the antigen-binding fragment thereof comprises a human constant region in which an amino acid is substituted with a cysteine residue, wherein said amino acid is position 140 of human IgG heavy chain region in EU numbering, and wherein the transformant comprises a recombinant vector comprising a DNA encoding the IgG monoclonal antibody or the antigen-binding fragment thereof, and wherein said method further comprises chemically modifying said substituted cysteine residue.
Specification